StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis Non-IFRS Free Cash Flow by Quarter

Non-IFRS Free Cash Flow ($M)

QuarterlyAnnual

Novartis Non-IFRS Free Cash Flow: $5,111M in Q3 2026, down 17.8% from a year earlier.

Latest, Q3 2026
5,111
Period ended Sep 30, 2026
Change on a year earlier
-17.8%
6,217 in Q3 2025
History
11 quarters
Since Q1 2024
Sources
7
Documents cited below

Where the Q3 2026 figure comes from

“|| Free cash flow | 5 111 | 6 217 | -18 | 14 002 | 15 941 | -12”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K (Free cash flow reconciliation).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-IFRS Free Cash Flow ($M)Year on yearSource
Q3 2026Sep 30, 20265,111-17.8%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 20265,561-12.2%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 20263,330-1.8%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 20251,655-54.5%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 20256,217+4.2%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 20256,333+37.2%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 20253,391+66.4%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 20243,635–Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 20245,965–Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 20244,615–Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 20242,038–Novartis Form 6-K (0001370368-25-000010) ↗

Cite this data

StockData. (2026). Novartis Non-IFRS Free Cash Flow ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/non-ifrs-fcf

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.